10-K: Medtronic Reports Strong Fiscal 2025 Growth Driven by Key Product Adoption, Announces Diabetes Business Separation

Medtronic plc reported a 4% increase in net sales and a significant rise in GAAP net income for fiscal year 2025, fueled by strong performance in its Cardiovascular, Neuroscience, and Diabetes segments, while also announcing plans to separate its Diabetes business.

Summary

• Medtronic plc achieved total net sales of $33.537 billion in fiscal year 2025, a 4% increase from $32.364 billion in fiscal year 2024.
• GAAP net income attributable to Medtronic rose to $4.662 billion in fiscal year 2025, up from $3.676 billion in fiscal year 2024, representing a 26.8% increase.
• Diluted GAAP earnings per share (EPS) increased to $3.61 in fiscal year 2025 from $2.76 in fiscal year 2024.
• Non-GAAP net income attributable to Medtronic was $7.079 billion, with non-GAAP diluted EPS of $5.49 for fiscal year 2025.
• Operating cash flow increased to $7.044 billion in fiscal year 2025 from $6.787 billion in fiscal year 2024.
• The company announced its intention in May 2025 to separate its Diabetes business into a new independent, publicly traded company, with completion expected within 18 months.
• Cardiovascular segment net sales grew by 5% to $12.481 billion, driven by Cardiac Ablation Solutions, Cardiac Rhythm Management, Structural Heart, and Cardiac Surgery.
• Neuroscience segment net sales increased by 5% to $9.846 billion, primarily due to growth in Neuromodulation, Spine and Biologics, and Neurosurgery.
• Diabetes segment net sales saw an 11% increase to $2.755 billion, attributed to strong U.S. adoption of the MiniMed 780G system and international growth in CGM systems.
• Medical Surgical segment net sales remained flat at $8.407 billion, with declines in Stapling offset by growth in Advanced Energy.
• The effective tax rate decreased to 16.6% in fiscal year 2025 from 23.4% in fiscal year 2024, primarily due to a valuation allowance on net operating losses and an income tax reserve adjustment in FY24, partially offset by Pillar Two Model Rules implementation in FY25.
• Medtronic repurchased 38 million shares in fiscal year 2025 at an average price of $83.36, with approximately $2.1 billion remaining under the share repurchase program.
• The company's total debt increased to $28.5 billion at April 25, 2025, from $25.0 billion at April 26, 2024, primarily due to a $3.2 billion Euro-denominated debt issuance in June 2024.

Sentiment

Score: 7

Explanation: The company demonstrated solid financial performance with increased sales and profitability, driven by strong segment growth and strategic product adoption. However, significant ongoing legal and tax challenges, along with macroeconomic headwinds and the complexities of a major divestiture, temper the overall positive sentiment.

Positives

• Overall net sales increased by 4% in fiscal year 2025, demonstrating continued revenue growth.
• GAAP net income attributable to Medtronic surged by 26.8% and diluted GAAP EPS by 30.8% in fiscal year 2025, indicating improved profitability.
• Operating cash flow increased by 3.8% to $7.044 billion, reflecting healthy cash generation from operations.
• The Diabetes segment showed strong growth of 11%, driven by the successful adoption of the MiniMed 780G automated insulin delivery system and Simplera Sync CGM.
• Cardiovascular and Neuroscience segments both grew by 5%, highlighting strength in core medical device markets and successful product launches like PulseSelect, Affera Sphere-9, Micra, Aurora EV-ICD, Evolut FX+ TAVR, Inceptiv SCS, and Percept RC DBS.
• The company's liquidity position is strong, with $2.2 billion in cash and cash equivalents and $6.7 billion in current investments as of April 25, 2025.
• Medtronic increased its quarterly cash dividend for Q1 fiscal year 2026 to $0.71 per share, demonstrating commitment to shareholder returns.
• The company continues to invest significantly in R&D, with expenses remaining flat at $2.7 billion, indicating ongoing commitment to innovation.

Negatives

• Free cash flow slightly decreased by 0.3% from $5.200 billion in fiscal year 2024 to $5.185 billion in fiscal year 2025.
• The Medical Surgical segment's net sales remained flat, impacted by declines in Stapling due to U.S. bariatric segment pressures and shifts to robotic surgery.
• The company recognized a $90 million incremental Italian payback accrual in fiscal year 2025, reducing net sales, following Constitutional Court rulings.
• Fiscal year 2024 included $439 million in pre-tax charges related to the decision to exit the ventilator product line, primarily due to intangible asset impairments and inventory write-downs.
• Net losses on minority investments were $213 million in fiscal year 2025, following $308 million in fiscal year 2024, indicating underperformance in some strategic investments.
• The company's total debt increased by $3.5 billion to $28.5 billion in fiscal year 2025, primarily due to new debt issuance.

Risks

• Intense competition in the medical device industry, including from large manufacturers, small specialized firms, and pharmaceutical companies (e.g., GLP-1s).
• Potential for reduction or interruption in supply of critical components and raw materials (e.g., semiconductors, resins, EtOs, PFAS), leading to manufacturing disruptions and lost sales.
• Adverse impacts from public health crises, geopolitical conflicts (e.g., Russia-Ukraine, Israel-Gaza), and changing global trade policies (e.g., tariffs, re-shoring initiatives).
• Inherent risks associated with investments and investment collaborations, with no guarantee of success or adverse effects on financial condition.
• Challenges in maintaining strong relationships with healthcare professionals, which are crucial for product development and marketing.
• Risks associated with debt obligations, including the need to use operating cash flow for interest/principal payments and potential inability to obtain favorable financing terms in the future.
• Difficulties in successfully integrating acquired businesses or realizing expected benefits from divestitures, such as the planned separation of the Diabetes business.
• Extensive and complex governmental regulations (e.g., U.S. FDA, EU MDR, NMPA), with potential for delays in regulatory approvals, adverse regulatory actions, and increased compliance costs.
• Product quality problems leading to recalls, safety alerts, product liability claims, and reputational harm.
• Failure to comply with laws and regulations related to healthcare reimbursement (e.g., kickbacks, false claims, Physician Payments Sunshine Act), potentially leading to penalties and reduced demand.
• Extensive intellectual property litigation, which could result in significant damage awards, injunctions, or royalty payments, and challenges in protecting IP rights in certain countries like China.
• Healthcare policy changes, cost-containment measures, declining reimbursement rates, and national/provincial tender pricing (especially in China) putting pressure on product prices and sales.
• Reliance on the proper function, security, and availability of information technology systems and data, with risks of cyber-attacks, data breaches, and disruptions, including those related to AI systems.
• Failure to comply with anti-corruption laws (e.g., FCPA, U.K. Bribery Act) in international operations, potentially leading to sanctions and reputational damage.
• Impacts of climate change, including severe weather events, increased operational costs, supply chain disruptions, and new environmental regulations.
• Risks related to sustainability practices and initiatives, including failure to meet targets, regulatory fines, and adverse publicity.
• Potential inadequacy of the company's self-insurance program to cover future losses.
• Changes in tax laws (e.g., OECD Pillar Two Model Rules) or exposure to additional income tax liabilities from ongoing tax audits and litigation (e.g., Puerto Rico manufacturing income allocation dispute with the IRS).
• Risks associated with being incorporated in Ireland, where laws differ from U.S. laws and may afford less protection to shareholders, including potential Irish stamp duty and dividend withholding tax.
• Market disruptions, diminished liquidity, and healthcare professional/staff strikes or work stoppages affecting demand and financial performance.
• Consolidation in the healthcare industry and the growing prevalence of ambulatory surgery centers (ASCs) leading to increased pricing pressure and potential loss of customers.

Future Outlook

Medtronic anticipates continued strong revenue growth driven by its attractive end markets, recent product launches, and robust pipeline. The company expects to accelerate innovation, deliver superior patient and provider outcomes, and leverage data, AI, and automation to tailor therapies and create new standards of care. Macroeconomic factors such as competitive pricing, global trade policies, currency fluctuations, and reimbursement challenges are expected to continue impacting the business. The net tariff impact for fiscal year 2026 is estimated to be between $200 million and $350 million. The separation of the Diabetes business is expected to be completed within 18 months of the May 2025 announcement. The company also expects continued global penetration of its Micra transcatheter pacing portfolio, adoption of Aurora EV-ICD, growth in electrophysiology products (PulseSelect, Affera Sphere-9), and acceptance of the Evolut TAVR platform. In Neuroscience, continued adoption of the AiBLE ecosystem, new spine products, and growth in neuromodulation therapies are anticipated. For Medical Surgical, the focus is on transitioning to minimally invasive surgery, global adoption of robotic-assisted surgery (Hugo RAS system), and continued growth in patient monitoring. The Diabetes segment anticipates continued acceptance and growth for the MiniMed 780G and Simplera systems, and expansion of CGM options through partnerships.

Management Comments

• "Our Mission – to alleviate pain, restore health, and extend life – empowers us to engineer the extraordinary and deliver better outcomes for our world."
• "We are embracing our role as a healthcare technology leader and evolving our business strategy in three key areas: Accelerate innovation-driven growth; Deliver superior outcomes and better experiences for patients and providers; and Turn data, artificial intelligence (AI), and automation into action."
• "We are confident in our ability to maximize new technology, AI, and data and analytics to tailor therapies in real-time, facilitating remote monitoring and care delivery that conveniently manages conditions, and creates new standards of care."
• "We remain committed to developing technological enhancements and new indications for existing products, and less invasive and new technologies for new and emerging markets to address unmet patient needs."
• "Our marketing and sales strategy is focused on rapid, cost-effective delivery of high-quality products to a diverse group of customers worldwide."
• "We strive to be the employer of choice for the best and brightest global talent, where employees can grow and develop fulfilling careers. We aspire to create an inclusive, diverse, and equitable workplace that fosters innovation and creativity, and where employees feel a sense of belonging and well-being."
• "Our culture is critical to achieving our vision. The Medtronic Mindset builds on our core values of integrity, quality, inclusion, and collaboration. It urges us to act boldly, compete to win, move with speed and decisiveness, foster belonging, and deliver results the right way."

Industry Context

Medtronic operates in a highly competitive and rapidly evolving global healthcare technology market, characterized by continuous technological advancements, scientific discoveries, and increasing cost containment pressures. The company faces competition from a diverse range of manufacturers, from large diversified players to small specialized firms, and increasingly from pharmaceutical companies, particularly with the rise of GLP-1s impacting bariatric surgery volumes. The industry is also navigating stringent and unpredictable global regulatory environments, such as the EU MDR, and evolving data privacy and cybersecurity laws. Geopolitical tensions and trade policies, including tariffs, continue to impact global supply chains and market access. Medtronic's strategic focus on innovation, AI integration, and expanding international presence aligns with broader industry trends towards personalized medicine, digital health, and addressing unmet patient needs in emerging markets. The planned separation of the Diabetes business reflects a trend towards portfolio optimization and creating more focused entities to unlock value in specific high-growth areas.

Comparison to Industry Standards

• Medtronic's 4% net sales growth in FY25 is in line with or slightly above the typical growth rates for large, diversified medical device companies, which often range from low to mid-single digits, but may lag behind some high-growth, specialized segments or smaller, agile competitors.
• The company's significant GAAP net income and EPS increase (26.8% and 30.8% respectively) suggests strong operational leverage and effective cost management, potentially outperforming some peers facing higher inflationary pressures or R&D costs.
• The flat performance in the Medical Surgical segment, particularly the decline in Stapling due to bariatric surgery pressures and shifts to robotics, indicates a challenge in adapting to market shifts, a common issue for established players facing disruptive technologies or new therapeutic alternatives (e.g., GLP-1s impacting bariatric surgery, where companies like Johnson & Johnson's Ethicon or Intuitive Surgical's da Vinci system are key competitors).
• The 11% growth in the Diabetes segment, driven by MiniMed 780G and Simplera Sync, positions Medtronic competitively against major diabetes technology players like Dexcom (CGM) and Abbott (FreeStyle Libre), indicating successful product adoption in a high-growth market.
• The ongoing tax litigation with the IRS regarding income allocation to Puerto Rico is a significant and prolonged issue, similar to tax disputes faced by other multinational corporations with complex international structures, such as Apple or Google, though the specifics of the dispute are unique to Medtronic's historical operations.
• The company's credit ratings (S&P: A/A-1, Moody's: A3/P-2) reflect a strong investment-grade profile, comparable to other large, stable healthcare companies like Johnson & Johnson (S&P: AAA, Moody's: Aaa) or Abbott Laboratories (S&P: A+, Moody's: A2), indicating robust financial health and access to capital markets.

Management Changes

Corporate Governance

Legal Proceedings

• **Colibri Heart Valve LLC Patent Litigation:** Medtronic is a defendant in a patent infringement lawsuit in California, where a jury returned a verdict of approximately $106 million against the company in February 2023. Medtronic appealed the decision in July 2023, and currently does not believe a loss is probable, thus no expense has been recognized.
• **Hernia Mesh Litigation:** Medtronic and its subsidiaries are defendants in approximately 9,325 individual lawsuits in U.S. state and federal courts alleging personal injury from hernia mesh products. The company has not recorded an expense for damages as any potential loss is not currently probable or reasonably estimable.
• **Diabetes Pump Retainer Ring Litigation:** Nine lawsuits involving 20 individuals have been filed against the Diabetes operating unit, alleging personal injury from Series 600 insulin pumps. Medtronic has not recorded an expense for damages as any potential loss is not currently probable or reasonably estimable.
• **Applied Medical Antitrust Litigation:** Medtronic is a defendant in a civil antitrust lawsuit in California, alleging anticompetitive and monopolistic conduct related to advanced bipolar devices. The trial has been deferred, and the company has not recorded an expense for damages as any potential loss is not currently probable or reasonably estimable.
• **Environmental Proceedings:** The company is involved in various environmental remediation and cleanup actions, including a lawsuit related to mercury contamination of the Penobscot River and Bay, for which a settlement was approved in October 2022 without a change to the company's previous accrual.
• **Anti-Corruption Matters:** Medtronic has ongoing interactions with governmental agencies (e.g., SEC, DOJ) and self-discloses potential concerns regarding activities in global markets. No expense has been recorded as any potential loss is not currently probable or reasonably estimable.
• **Italian Payback:** Following two July 2024 rulings by the Constitutional Court of Italy finding the medical device payback law constitutional, Medtronic increased its liability by $90 million, recognized as a reduction to net sales. Final resolution is still pending.
• **Contract Termination with Blackstone:** Medtronic recognized certain litigation charges in fiscal year 2025 related to a contractual dispute resolution under one of its funded research and development arrangements with Blackstone.
• **IRS Tax Litigation (Puerto Rico Manufacturing):** An unresolved issue with the IRS regarding the allocation of income between Medtronic, Inc. and its Puerto Rico subsidiary for fiscal years 2005 and 2006 is ongoing. The Tax Court issued a second opinion in August 2022, which was appealed by the IRS in September 2023, and Medtronic cross-appealed in October 2023. Oral arguments occurred in May 2025. An adverse outcome could materially impact financial condition. Total uncertain tax benefits related to this and other matters were $2.902 billion at April 25, 2025.

Related Party Transactions

• Medtronic has entered into various arrangements with affiliates of Blackstone Life Sciences Advisors L.L.C. (Blackstone) to receive funding for the development of certain products within the Cardiovascular Portfolio and Diabetes Operating Unit. Under these arrangements, Medtronic recognized income of $181 million in fiscal year 2025. Blackstone is eligible to receive fixed regulatory and commercial milestone payments up to $1.2 billion and royalties based on product sales following regulatory approval and commercial launch.

Stakeholder Impact

• **Shareholders:** Experienced increased GAAP net income and EPS, and an increased quarterly dividend. The ongoing share repurchase program also benefits shareholders. However, the planned separation of the Diabetes business introduces uncertainty but could unlock value. Legal and tax disputes, and macroeconomic factors, pose potential risks to shareholder value.
• **Employees:** The company emphasizes inclusion, pay equity, and professional development. Restructuring initiatives, including employee termination benefits, impact some employees. The company provides robust health and safety support, including an Employee Assistance Program and Emergency Assistance Fund.
• **Customers/Providers:** Benefit from Medtronic's focus on innovation, superior outcomes, and integration of AI and data analytics. However, cost containment measures, declining reimbursement rates, and industry consolidation may affect their purchasing decisions and access to products.
• **Suppliers:** Face potential disruptions due to supply chain challenges (e.g., semiconductor shortages, regulatory changes for chemicals like EtOs and PFAS) and geopolitical events. The company works closely with suppliers to ensure continuity.
• **Creditors:** The company's strong financial position and investment-grade credit ratings (A/A-1 by S&P, A3/P-2 by Moody's) indicate a low credit risk. The increase in total debt is managed within the company's capital structure strategy.

Next Steps

• Complete the separation of the Diabetes business into a new independent, publicly traded company within 18 months of the May 2025 announcement.
• Continue to drive global penetration of the Micra transcatheter pacing portfolio and adoption of Aurora EV-ICD.
• Further grow and gain acceptance for innovative electrophysiology products, including PulseSelect and Affera Sphere-9.
• Expand market acceptance and reimbursement for the Symplicity Spyral renal denervation system.
• Continue adoption and growth of integrated solutions through the AiBLE offering in Neuroscience, including new spine products and next-generation enabling technologies.
• Pursue U.S. FDA approval for the Hugo robotic-assisted surgery (RAS) system.
• Develop and commercialize products within the pipeline, including next-generation insulin delivery options and expanded labeling in Type 2 diabetes.
• Actively work to resolve remaining pay inequities by continuing to expand annual pay equity analyses for each country of operation.
• Seek new authorizations for share issuance at the 2025 Annual General Meeting and in subsequent years.
• Monitor and mitigate the effects of tariffs, with an estimated net tariff impact of $200 million to $350 million in fiscal year 2026.
• Continue to defend against intellectual property litigation, including the Colibri patent litigation and Applied Medical antitrust litigation.
• Monitor and resolve the ongoing IRS tax litigation regarding Puerto Rico manufacturing income allocation.
• Address the final resolution of the Italian payback litigation and potential impacts on liability.

Key Dates

Recommendation

Keywords

Medical Devices, Healthcare Technology, SEC Filing, 10-K, Financial Results, Medtronic, Cardiovascular, Neuroscience, Medical Surgical, Diabetes, Product Launches, Regulatory Approvals, Risk Factors, Litigation, Taxation, Supply Chain, Artificial Intelligence, Corporate Governance, Share Repurchase, Dividends, Mergers and Acquisitions, Divestitures, Global Operations, Reimbursement, Intellectual Property